Published in J Biol Chem on February 07, 2006
Cartilage biology in osteoarthritis--lessons from developmental biology. Nat Rev Rheumatol (2011) 1.19
Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis (2010) 1.09
Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab (2012) 1.03
Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. PLoS One (2011) 1.02
BMP2 and mechanical loading cooperatively regulate immediate early signalling events in the BMP pathway. BMC Biol (2012) 0.99
Early effects of embryonic movement: 'a shot out of the dark'. J Anat (2006) 0.97
TLR2 activation enhances HIV nuclear import and infection through T cell activation-independent and -dependent pathways. J Immunol (2011) 0.85
Reduced chondrogenic matrix accumulation by 4-methylumbelliferone reveals the potential for selective targeting of UDP-glucose dehydrogenase. Matrix Biol (2011) 0.82
Different magnitudes of tensile strain induce human osteoblasts differentiation associated with the activation of ERK1/2 phosphorylation. Int J Mol Sci (2008) 0.82
Rosiglitazone inhibits alpha4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor gamma-independent signals. Mol Cancer Ther (2009) 0.80
Signal pathways regulating hyaluronan secretion into static and cycled synovial joints of rabbits. J Physiol (2009) 0.76
Signaling networks in joint development. Dev Dyn (2016) 0.75
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev (2004) 9.54
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev (2002) 8.31
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene (2004) 7.92
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A (2008) 6.84
mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell (2005) 6.71
Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol (2002) 6.05
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science (2011) 5.73
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol (2004) 5.46
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A (2004) 5.16
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 4.93
The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol (2008) 4.92
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem (2007) 4.45
Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell (2010) 4.07
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol (2003) 4.01
MAPK signal specificity: the right place at the right time. Trends Biochem Sci (2006) 3.96
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci (2011) 3.89
Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol (2005) 3.89
Identification of a conserved motif required for mTOR signaling. Curr Biol (2002) 3.78
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J (2006) 3.57
SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell (2008) 3.43
ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell (2010) 3.03
Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem (2005) 2.84
mTOR, translational control and human disease. Semin Cell Dev Biol (2004) 2.77
The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell (2013) 2.70
Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle (2009) 2.45
A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions. Dev Cell (2010) 2.40
Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res (2002) 2.37
Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol Cell Biol (2003) 2.32
A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol Cell Biol (2004) 2.30
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A (2005) 2.23
Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem (2003) 2.12
SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell (2013) 1.99
Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci U S A (2011) 1.90
SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol (2004) 1.90
Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol Cell Biol (2004) 1.81
PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol (2004) 1.78
The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci (2008) 1.75
Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol (2013) 1.73
Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A (2008) 1.69
Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production. Am J Pathol (2004) 1.56
Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex. Mol Cell (2012) 1.50
PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration. Am J Physiol Cell Physiol (2003) 1.49
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. FEBS Lett (2005) 1.48
Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo. Curr Biol (2005) 1.46
Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol Cell Biol (2004) 1.43
Graded mitogen-activated protein kinase activity precedes switch-like c-Fos induction in mammalian cells. Mol Cell Biol (2005) 1.42
Nutrient regulation of the mTOR complex 1 signaling pathway. Mol Cells (2013) 1.42
The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr Biol (2005) 1.38
Ran-binding protein 3 phosphorylation links the Ras and PI3-kinase pathways to nucleocytoplasmic transport. Mol Cell (2008) 1.33
TORgeting oncogene addiction for cancer therapy. Cancer Cell (2006) 1.30
Osteocytes use estrogen receptor alpha to respond to strain but their ERalpha content is regulated by estrogen. J Bone Miner Res (2006) 1.25
ERK-MAPK drives lamellipodia protrusion by activating the WAVE2 regulatory complex. Mol Cell (2011) 1.22
Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta. Cancer Res (2009) 1.20
Sympathetic nervous system does not mediate the load-induced cortical new bone formation. J Bone Miner Res (2005) 1.19
Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-dependent regulation. J Biol Chem (2005) 1.17
p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling. J Biol Chem (2009) 1.16
Aging enhances a mechanically-induced reduction in tendon strength by an active process involving matrix metalloproteinase activity. Aging Cell (2007) 1.14
PHLPPing it off: phosphatases get in the Akt. Mol Cell (2007) 1.14
Early activation of the p42/p44MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism. FASEB J (2002) 1.13
Characterizing the interaction of the mammalian eIF4E-related protein 4EHP with 4E-BP1. FEBS Lett (2004) 1.12
Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem (2006) 1.12
From flat foot to fat foot: structure, ontogeny, function, and evolution of elephant "sixth toes". Science (2011) 1.11
Characterizing a novel and adjustable noninvasive murine joint loading model. Arthritis Rheum (2011) 1.11
Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1. J Biol Chem (2002) 1.08
Evaluation of VEGF-mediated signaling in primary human cells reveals a paracrine action for VEGF in osteoblast-mediated crosstalk to endothelial cells. J Cell Physiol (2008) 1.08
Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology (2008) 1.07
Osteoblast-like cells from estrogen receptor alpha knockout mice have deficient responses to mechanical strain. J Bone Miner Res (2004) 1.03
Cell signaling in protein synthesis ribosome biogenesis and translation initiation and elongation. Prog Mol Biol Transl Sci (2009) 1.03
AKT facilitates EGFR trafficking and degradation by phosphorylating and activating PIKfyve. Sci Signal (2013) 1.03
Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. PLoS One (2011) 1.02
Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts. Arthritis Rheum (2008) 1.02
Using digital image correlation to determine bone surface strains during loading and after adaptation of the mouse tibia. J Biomech (2009) 1.02
Inhibition of ERK-MAP kinase signaling by RSK during Drosophila development. EMBO J (2006) 1.01
Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints. Arthritis Rheum (2002) 0.97
Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med (2014) 0.97
Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling. J Biol Chem (2012) 0.97
Time-series transcriptional profiling yields new perspectives on susceptibility to murine osteoarthritis. Arthritis Rheum (2012) 0.96
Mind the GAP: Wnt steps onto the mTORC1 train. Cell (2006) 0.95
Regulation of UDP-glucose dehydrogenase is sufficient to modulate hyaluronan production and release, control sulfated GAG synthesis, and promote chondrogenesis. J Cell Physiol (2011) 0.95
Fatty acid composition of chylomicron remnant-like particles influences their uptake and induction of lipid accumulation in macrophages. FEBS J (2006) 0.94
Selective activation of the MEK-ERK pathway is regulated by mechanical stimuli in forming joints and promotes pericellular matrix formation. J Biol Chem (2005) 0.94
Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis. Proc Natl Acad Sci U S A (2013) 0.92
Human osteoblasts' proliferative responses to strain and 17beta-estradiol are mediated by the estrogen receptor and the receptor for insulin-like growth factor I. J Bone Miner Res (2002) 0.92
Postprandial lipoproteins and the molecular regulation of vascular homeostasis. Prog Lipid Res (2013) 0.92
Rheb activation of mTOR and S6K1 signaling. Methods Enzymol (2006) 0.90
Hippo-YAP and mTOR pathways collaborate to regulate organ size. Nat Cell Biol (2012) 0.90
Human endothelial Pyk2 is expressed in two isoforms and associates with paxillin and p130Cas. Biochem Biophys Res Commun (2002) 0.90
A high-throughput, cell-based screening method for siRNA and small molecule inhibitors of mTORC1 signaling using the In Cell Western technique. Assay Drug Dev Technol (2010) 0.89
Protease-activated receptors upregulate cyclooxygenase-2 expression in human endothelial cells. Thromb Haemost (2002) 0.88
Diverse range of fixed positional deformities and bone growth restraint provoked by flaccid paralysis in embryonic chicks. Int J Exp Pathol (2003) 0.87